Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

46.80 -0.19 (-0.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,683,109
Open 47.08
Bid (Size) 47.13 (12)
Ask (Size) 47.97 (1)
Prev. Close 46.99
Today's Range 46.38 - 47.10
52wk Range 45.22 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 4.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering... 
Via Benzinga
Topics Government
Exposures Political Product Safety
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
Via The Motley Fool

Performance

YTD
-6.40%
-6.40%
1 Month
-5.47%
-5.47%
3 Month
-18.08%
-18.08%
6 Month
+1.19%
+1.19%
1 Year
-2.99%
-2.99%

More News

Read More
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
NVIDIA Invested in These 2 AI Stocks, Should You?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY.
Via Chartmill
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Bird Flu Found In Raw Milk Leads To Recall In California
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Via Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Via Benzinga
Exposures Product Safety
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Why Sanofi Stock Flew Higher on Friday
Via The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.